- Conditions
- Non Alcoholic Steatohepatitis (NASH)
- Interventions
- Tropifexor, Licogliflozin, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 28
- States / cities
- Dothan, Alabama • Coronado, California • Los Angeles, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 572
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
- Interventions
- Alpelisib 300 mg, Placebo, [1-13C] sodium acetate, [6,6-2H2] D-glucose, Mixed Meal Tolerance Test, Nestlé BOOST Plus
- Drug · Diagnostic Test · Dietary Supplement
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
- Interventions
- Samples
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Experimental: Low-fructose, reduced carbohydrate diet, General Healthy Diet
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Non-Alcoholic Steatohepatitis (NASH)
- Interventions
- Pemvidutide, Placebo
- Drug
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 29
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 23 more
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- AMG 609, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Chandler, Arizona • Chula Vista, California • Montclair, California + 5 more
- Conditions
- Type II Diabetes, Nonalcoholic Fatty Liver
- Interventions
- DPP4 inhibitor, Pioglitazone, Lantus insulin
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- Magnetic Resonance Imaging (MRI), Ultrasound Imaging
- Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- NAFLD, NASH
- Interventions
- DD01, Placebo
- Drug
- Lead sponsor
- Neuraly, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Maitland, Florida • Monroe, Louisiana • West Monroe, Louisiana + 8 more
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity
- Interventions
- Alternate day fasting, Exercise
- Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
- Interventions
- Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
- Drug · Diagnostic Test
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- NAFLD, Diabetes, Obesity
- Interventions
- GLP-1 receptor agonist
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Non-Alcoholic Steatohepatitis
- Interventions
- Suspected NASH BreathID test with 13C-Octanoate, Suspected NASH Breath test with 13C Methacetin
- Device
- Lead sponsor
- Meridian Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Forts Sam Houston, Texas • Houston, Texas + 3 more
- Conditions
- Non-alcoholic Fatty Liver Disease, Childhood Obesity, Insulin Resistance
- Interventions
- Carbohydrate-restricted diet, Control, low-fat diet
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- CS0159 (Linafexor)
- Drug
- Lead sponsor
- Cascade Pharmaceuticals, Inc
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 17
- States / cities
- Gardena, California • Huntington Park, California • Panorama City, California + 13 more
- Conditions
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
- Interventions
- HU6, Placebo
- Drug · Other
- Lead sponsor
- Rivus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 20
- States / cities
- Chula Vista, California • Los Angeles, California • Montclair, California + 13 more
- Conditions
- Non-Alcoholic Fatty Liver Disease, Steatosis of Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Interventions
- STIRRED
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,704 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Month and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- San Francisco, California • Bethesda, Maryland • Chapel Hill, North Carolina + 2 more
- Conditions
- Nonalcoholic Fatty Liver
- Interventions
- PXL770, Placebo Oral Capsule
- Drug
- Lead sponsor
- Poxel SA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Gainesville, Florida • Ocoee, Florida + 11 more
- Conditions
- Fatty Liver Disease, Fibrosis, Liver, Cirrhosis, Liver, Steatohepatitis, Nonalcoholic
- Interventions
- Align Probiotic Supplement Capsule, Placebos
- Drug
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Farmington Hills, Michigan
- Conditions
- Insulin Resistance, Hyperinsulinemia, Dyslipidemias
- Interventions
- Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), Placebo (microcrystalline cellulose), 2 capsules, FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage, BOOST Plus nutritional beverage
- Drug · Device · Diagnostic Test + 1 more
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 14
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
- Conditions
- NAFLD
- Interventions
- Semaglutide Pen Injector, Placebo
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- NAFLD, Diabetes Mellitus
- Interventions
- NAFLD Education, diet/lifestyle support, T2D medication management, clinically-indicated liver testing and care
- Behavioral · Drug · Diagnostic Test
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina